Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

This prevention trial (n=80) will assess the effect of a subanaesthetic dose of esketamine on preventing postoperative depression in patients undergoing cardiac surgery.

Esketamine, known for its antidepressant effects, will be intravenously infused before anaesthesia induction. The study aims to determine if this intervention can prevent or mitigate postoperative depressive symptoms common in cardiac surgery patients.

The trial, conducted by Anshi Wu at Beijing Chao Yang Hospital, Capital Medical University, involves patients aged 18 and above with moderate to severe depressive symptoms scheduled for heart surgery. The primary completion date was in December 2021, with the study estimated to be completed by December 2022.

It is a randomised, double-blind, placebo-controlled pilot and feasibility trial, with primary outcome measures including response rate and secondary measures such as anxiety symptoms, postoperative delirium, and quality of life.

Trial Details

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

Trial Number NCT05155969

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.